Vaxart, Inc. (VXRT) Earnings Call Transcript & Summary

August 7, 2026

OTC Pink Market US Health Care Biotechnology earnings 44 min

Earnings Call Speaker Segments

David Carey

executive
#1

Vaxart's Steve Lo, our Chief Executive Officer, is joining us today, along with Founder and Chief Scientific Officer Dr. Sean Tucker; Chief Medical Officer Dr. James F. Cummings; Chief Financial Officer Jeroen Grasman; and Ed Berg, who holds the titles of Senior Vice President and General Counsel. Before we begin, I'd like to note that during today's call, Vaxart could make forward-looking statements. These may cover the company's financial results and guidance, future business strategies and operations, partnerships with third parties, when anticipated regulatory approvals might come or whether they will be secured at all, how long the company's cash will last, its capacity to raise capital, and progress on product development and regulatory matters, including remarks about clinical trials that are underway or planned. Several significant elements might lead real outcomes to diverge substantially from what these forward-looking statements describe. Among them are the unpredictability that naturally exists within clinical development and the regulatory pathway, along with additional risk factors laid out in the Risk Factors portion of Vaxart's latest annual report on Form 10-K as well as periodic reports submitted to the SEC. Vaxart assumes no duty to revise any forward-looking statements following today's call. At this point I'll hand things over to Steven Lo. Steve?

Steve Lo

executive
#2

Thanks, David. Good afternoon, everyone, and I appreciate you being with us. For Vaxart, the second quarter along with recent weeks represented a crucial stretch of execution and advancement. During July, we hit an important milestone in our Phase IIb COVID-19 trial by reporting positive 12-month safety data from our sentinel cohort. These findings gave us encouraging validation regarding the safety of our oral pill platform as we get ready to report top line data from the main cohort of approximately 5,000 participants during the first half of 2027. We could release this data once we completed a contract modification with our partners at BARDA in June, which additionally freed up dedicated funding so we can carry out a far deeper scientific analysis of the trial data. I want to offer my sincere thanks to our hard-working Vaxart employees as well as the trial participants, clinical investigators, and study coordinators at all our sites. The commitment shown by these participants and the research teams in running a trial of this scale and pushing our needle-free vaccine forward is what makes our progress possible. Regarding business development, we keep looking for a partnership for our norovirus program and have continued to see partner interest. We are approaching these discussions in a disciplined way to make sure any next steps capture the full value of this asset and serve the best interest of our shareholders. At this moment, it is critical that we concentrate on finishing the Phase IIb COVID-19 trial, which is our most immediate value driver; beyond our clinical momentum, we have taken important steps to strengthen our corporate governance and to engage openly and constructively with our stockholders, making sure we stay strongly aligned. Our choice to enter into a cooperation agreement with the shareholder group shows our commitment, along with our Board's commitment, to strong governance, disciplined oversight, and constructive engagement with our shareholders. As part of these governance enhancements, we reorganized Board leadership and appointed new committee chairs, with Kevin Finney leading our Nominating and Governance Committee and Dr. Jim Breitmeyer chairing our Compensation Committee. In addition, we are forming the Stockholder Engagement Committee and the Clinical and Regulatory Affairs Committee. We are also searching for an additional independent director to add to the Board, working closely with the shareholder group as set out in our collaboration agreement. We believe these actions significantly strengthen Board oversight and reinforce our commitment to shareholder dialogue. I'll turn the call over to James to walk us through the details of the COVID-19 data readout. James?

James Cummings

executive
#3

Appreciate that, Steve, and I want to thank everybody who's joined us today. As Steve noted, back in July we had good news to share: we reported positive 12-month safety results from the 400 participant sentinel cohort in our Phase IIb COVID-19 trial, which BARDA funds through its Project NextGen initiative. For some context, a sentinel cohort is essentially a smaller set of participants who get vaccinated first so safety can be assessed before you move on to a far bigger study population. This cohort gave us our first direct head-to-head comparison of the safety of Vaxart's oral pill vaccine versus an approved injectable mRNA vaccine. For this particular cohort, the shots were designed to go after the XBB strain of SARS-CoV-2 — that's the pathogen behind COVID-19 — and enrollment broke down as 201 people receiving our oral tablet versus 199 who got the injected mRNA shot. This arm of the study was chiefly about checking safety and how well subjects tolerated treatment, and what came back was quite positive. Across both arms, there were zero serious health issues tied to the vaccine and zero adverse events that were severe or lingering. As for the routine, day-to-day reactions, the profile for our tablet looked really good. Among those who took the pill, the side effects most often reported were fatigue that was mild to moderate, running about 20.9%, then headache at 18.9%, and roughly 10% noted a diminished appetite. Really, under 10% of those enrolled dealt with any remaining side effects. Conversely, among those who received the mRNA shot, adverse reactions occurred more often both where the needle went in and across the rest of the body. Injection site pain was reported by more than 60% of mRNA recipients. Tenderness at the injection site was reported by 40.2%, fatigue by 35.2%, muscle pain by 33.2%, and headaches by 28.6%. Furthermore, between 10% and 15% of mRNA participants also reported joint pain, chills, nausea, diarrhea, and arm swelling. Our technology anticipated exactly these results. With a pill, there is no injection, so injection site pain disappears. Local swelling and systemic discomfort of that kind are generally associated with needle-delivered mRNA vaccines, whereas a pill-based vaccine does not produce them. When it came to COVID-19 infections among the 400 people in this study, symptomatic cases showed up in 33 of those who received the oral pill and 30 of those who got the mRNA shot. By symptomatic, we mean they displayed the usual signs of COVID-19. Within each of those groups, 12 people turned out to have asymptomatic infections — they tested positive for SARS-CoV-2, the virus responsible for COVID-19, despite showing no symptoms at all. I want to stress something here: this sentinel group of 400 was deliberately set up to capture a safety signal — basically to understand the safety profile — not to scientifically demonstrate a statistical difference between the two vaccines when it comes to protection. The primary group we're analyzing — roughly 5,000 people who received the KP.2-targeted vaccine — gives us sufficient scale to tell apart chance occurrences from those tied to the specific vaccine given. That core group has reached its full enrollment and carries the statistical power needed to deliver meaningful answers regarding both safety and how well it performs compared with alternatives. Thanks to the modification we signed with BARDA back in June, we're now positioned to dig much deeper into our trial's data. So that includes examining mucosal immunity, meaning we measure antibody protection right where the virus enters — the nose and the mouth — plus broader immune and safety assessments. Those deeper analyses are underway at the moment, though we're not able at this stage to say when results will be shared. As I mentioned, this sits within our arrangement with BARDA, which means that agency has final authority over any readout. And per what Steve noted earlier, we anticipate sharing top line data from the primary cohort — about 5,000 people — sometime in the first half of 2027. Right now, I'll hand things over to Jeroen so he can walk us through the financials. Jeroen?

Jeroen Grasman

executive
#4

Thanks, James. So at the close of 2026's second quarter, Vaxart held $64 million across cash, cash equivalents, and short-term investments. Under the operating plan we have in place right now, our expectation remains that this capital carries the business into the second quarter of 2027. Turning to revenue, the second quarter of 2026 brought in $27.2 million, versus $39.7 million during the same period of 2025. Most of that came from our government contract with BARDA, plus $2.9 million tied to the license and collaboration agreement we entered into with Dynavax in November of last year. R&D expenses for the quarter totaled $33.7 million, a drop from $49.7 million a year earlier. That net decrease largely reflects lower clinical trial spending on Vaxart's COVID-19 vaccine candidate, alongside reduced personnel costs, facilities costs, and pre-clinical manufacturing costs. G&A expenses came to $6.6 million for the quarter. On the bottom line, Vaxart posted a net loss of $13.5 million, or $0.06 per share, against a net loss of $15 million, or $0.07 per share, in 2025's second quarter. On top of that, our $25 million share purchase agreement with Lincoln Park Capital is still open, which gives us flexible capital access entirely at our discretion; we're staying committed to disciplined financial management and looking at non-dilutive funding avenues, including government grants and non-dilutive partnerships, as we push toward our upcoming clinical milestones. Now I'll pass the call back to David for your questions.

David Carey

executive
#5

Okay, thanks Jeroen. We've gotten a lot of shareholder questions ahead of time, and we sort them out by topic. So we'll start with the ones that came in by e-mail before now, and after that we'll go to live questions arriving via the webcast portal. The first group of questions has to do with COVID-19, and James, would you mind handling this one? It's about when shareholders ought to see efficacy on that 5,000 participant study. And when should comparative immunogenicity data be expected from the COVID study with roughly 400 subjects? That's 2 questions there. And also, will the data contain meaningful comparisons against mRNA vaccines that are available right now?

James Cummings

executive
#6

Appreciate the question. So the top line efficacy and safety data are expected to come out in the first half of 2027, drawn from the full study set — that's the 400 participants in the sentinel safety cohort plus, as I noted, roughly 5,000 participants in the main cohort. When it comes to immunogenicity data from those 400 or so in the sentinel cohort, the Phase IIb trial was set up under an award from BARDA. One central requirement of the design for this BARDA-funded trial is to directly assess relative efficacy, safety, and immunogenicity of Vaxart's oral pill vaccine versus an active approved injectable mRNA vaccine comparator; we're pushing that process forward actively. So at this moment, we can't give a specific time line for reporting. Part of the reason is that our contract with BARDA, as I said, gives the agency authority over when and what content appears in all the readouts we put out.

David Carey

executive
#7

Thanks, James. Sean, would you mind handling the following question? Given that COVID is mutating quickly and, in certain cases, undergoing significant changes — for instance, moving from XBB to KP2 to XFG and Takeda — is IgA capable of dealing with mutations that carry such a high degree of divergence?

Sean Tucker

executive
#8

Absolutely, and I appreciate you raising that. It's well established that IgA can tackle variants more effectively than IgG can, and it's also well established that our technology generates robust mucosal IgA reactions. As is common knowledge, we shared earlier that our oral COVID-19 vaccine showed wide cross-reactivity against numerous SARS-CoV-2 variants, and additionally against other coronaviruses; therefore, we genuinely believe our method will outperform an injected vaccine. Naturally, in the end, we'll learn far more regarding how well our vaccine performs once we review the analytical data from both the sentinel group and the main cohort of the COVID trial that is presently enrolling and — in fact, has completed enrollment yet remains ongoing, there's a substantial volume of data we expect to receive given how large the study is.

David Carey

executive
#9

Appreciate that, Sean. Moving on to James again. Do you happen to know the overall count of COVID cases, covering both those with symptoms and those without, that have shown up so far within the bigger group of 5,000? I realize the specifics aren't available to us at this point since everything remains blinded. Still, I'm just wondering whether you're aware of the overall number of positive COVID infections.

James Cummings

executive
#10

Appreciate that, Dave. Thanks for asking. So we continue to follow subjects and build up cases within that cohort of 5,000 people, as I noted earlier. What we intend to do is make that information available when we put out the data on the main cohort in 2027. Just to repeat, and I don't want to sound like a broken record, you need BARDA's approval before anything can be released, and on every data release we're coordinating with BARDA.

David Carey

executive
#11

All right, then, Sean is up next. Over to you, Sean. Dr. Cummings said earlier that when it comes to the COVID shot, the low dose and the high dose yield comparable IgA. With the NextGen construct, the high dose hasn't been studied in people, so did that come from the initial Phase I trial results from 2020/2021? Or did modeling drive it, to project what the IgA response would be at various doses? For noro, obviously, the gap was substantial.

Sean Tucker

executive
#12

Yeah, thank you for asking that. So, in earlier trials of the oral vaccine for COVID-19, we relied on those to inform how much to give; as an illustration, we observed that when administered as a booster to individuals who had gotten an mRNA shot before, both the lower and higher amounts of our oral pill vaccine produced comparable immune responses. Of course, each person enrolled in this trial has gotten an mRNA vaccine at some point previously, and we consider that a solid basis for choosing dosage; once immunological data has been examined, we'll gain improved understanding of how the immune system responds to the vaccine being used now, which will assist us in identifying suitable immune correlates and, once more, steer us toward deciding if testing a larger dose makes sense. Regarding the norovirus trial question, I'd like to note that indeed, a statistically significant gap appeared between the older norovirus construct and the next-generation norovirus construct when only the high dose was examined in that Phase I study. Once more, this is the trial conducted during 2025. And once more, that was excellent. We recognize that the newer constructs perform better. That said, comparing the high dose against the low dose of the next-generation norovirus construct, no statistical difference emerged, despite a minor numerical gap. Such a gap might simply stem from chance variation between individuals rather than an actual dose-related effect. I also want to mention and — remind everyone that the amount given for a single vaccine won't necessarily match across different disease targets, even when those vaccines rely on the very same platform.

David Carey

executive
#13

Appreciate that, Sean. James, handing it back your way. Despite the fact that the trial wasn't designed to measure efficacy, does it catch you off guard that the enhanced NextGen offering from Vaxart yielded infection rates comparable to mRNA, which as we're aware declines fast and acts more like a lock and key, exactly as you've described. Whatever became of the idea that Vaxart's offering would deliver cross-reactive protection along with longer-lasting immunity?

James Cummings

executive
#14

Thank you. To begin with, when it comes to efficacy, our oral vaccine candidate stacked up quite well against an authorized mRNA injection comparator, showing comparable effectiveness within this sentinel group; even so, the full data set here is encouraging. I want to stress that this group of 400 participants was mainly intended to assess safety; and as I mentioned, it truly does not have the statistical power needed to reach firm conclusions regarding how much efficacy or cross-reactive immunity is present in the study. Evaluating genuine mucosal protection along with long-term durability — which is the second portion of your question, David — calls for a substantially bigger clinical trial population followed across time. However, we will obtain deeper insight into how long the response lasts, the extent of broad cross-reactivity, and the relative or comparative efficacy once we get and examine the complete data readout from the main cohort of 5,000 — roughly 5,000 participants.

David Carey

executive
#15

Thanks, James. I have one more thing to ask. The sentinel cohort data came out later than the management team had first expected. Looking forward to the complete Phase IIb efficacy readout that's anticipated during the first half of 2027, do you have confidence that the processes and the agreements with BARDA are now established so those results can be released in a timely way?

James Cummings

executive
#16

I appreciate the question. What held up the sentinel cohort was mainly the usual BARDA collaboration procedures, under which the first set of data has to go through a government evaluation, plus the contract amendment I brought up a bit ago, so that it would capture the trial's scope after the stop work and pause orders. Now that those basic procedures and the contractual structure are completely in place, our people are taking those — truly, those essential operational lessons — and putting them straight into how this pivotal study is carried out. Even so, I want to stress again that, per the contract's terms, BARDA holds ultimate say over when every readout happens and what it contains. Keeping our data sound is essential. That's genuinely why sticking to those procedures matters so much; even so, we have a seasoned team that has overseen this kind of process, and it will keep doing so. The pivotal trial, involving roughly 5,000 participants, has already reached full enrollment and is moving forward actively. And I'm eager to share top line data during the first half of 2027. Each of us is entirely dedicated to hitting this central milestone as quickly as possible, given how large and complicated this study is, while producing data of the greatest possible fidelity.

David Carey

executive
#17

Thanks, James. Sean, this next one's directed at you. It looks like your oral COVID vaccine might have a role to play as a treatment for long COVID. Is that something worth looking into? Clearly, a big share of people are impacted. Have you ever been stopped in your car at a turning arrow and missed the turn because whoever's ahead of you wasn't paying attention, whereas pursuing this as a therapeutic could make the acceptance requirements easier.

Sean Tucker

executive
#18

Absolutely, and we appreciate the question — this is definitely something that grabs our attention. Once more, our outlook on what the COVID vaccine could offer as a therapy for long COVID is quite optimistic. Naturally, the root causes behind long COVID are still being studied, yet there's data suggesting that certain individuals with long COVID might carry low amounts of viral replication along with tiny reservoirs of replication inside their bodies; why the immune system is unable to wipe out the infection elsewhere in the body while those small reservoirs remain is not well understood, though we are aware that certain studies have reported their presence. We also know that such reservoirs can show up in the intestinal tract; and clearly, our approach of targeting the oral intestinal route might be able to accomplish something when it comes to tackling those tiny reservoirs of replication. I'd also mention, naturally, that it's evident this remains merely a hypothesis, and we would have to run an additional clinical trial involving long COVID patients and figure out whether our oral pill might eradicate or accomplish certain things that better those individuals' lives. In the end, as I mentioned earlier, the ultimate call on whether they <<inaudible>> ahead of the clinical trial, particularly for long COVID, rests with Sanofi.

David Carey

executive
#19

Appreciate that, Sean. All right, we'll turn to norovirus now. There are a few questions — in fact, quite a number of them came in. So Steve, would you mind handling this one? Given that Moderna's norovirus program is presently paused, and Vaxart has produced promising safety data from roughly 400 participants, has interest grown in talks with possible pharmaceutical partners? Without revealing anything confidential, could management give us some idea of the valuation range that's being discussed for a partnership?

Steve Lo

executive
#20

Appreciate it. Let me start by talking about Moderna's norovirus program. What came out in the news was that Moderna requires an additional season in order to finish enrolling patients in their study. So it isn't paused, but rather it's been stretched out, basically, by one more season, and that obviously pushes back the trial's timing. From where we sit, that's a bit of a double-edged sword. On one hand, we view them as a competitor. And the faster we can get our Phase II trial moving ahead, the better we can remain near them when it comes to presence in the market. So the fact that they're delayed, naturally, hands us somewhat of a competitive edge. That part is good. The less good part, which once again we'll always try hard to soften, is that there's now one more data point in the norovirus space where a company stumbled, HilleVax. Then there's Moderna, which keeps pushing out its time line. So whenever we speak with prospective partners, that's something they factor in too as they assess whether this is a worthwhile opportunity. As for the question about the valuation range, we typically don't share that, mainly since we don't want to bid against ourselves. I will say that at Vaxart, we see norovirus as highly valuable, and that's the reason we keep holding conversations with prospective partners. We believe this represents an enormous unmet need. Because of that, we keep pitching this to other prospective partners. And the Moderna data plus the reality that we do have positive safety data from the sentinel cohort, I'd say that has enabled us to contact companies that, shall we say, hadn't gotten back to us for a while, and it's helped us at least put the newest data on their radar in case they'd stopped following things. So in that sense, I'd call it useful.

David Carey

executive
#21

Alright, thanks Steve. The upcoming question is somewhat along the same lines. I’ll go ahead and read the whole thing. And I believe, Sean, if you might take this one, and afterward Steve, should you have anything to add. Here’s the question: management has said before that interest from potential partners in Vaxart’s norovirus program might grow after Moderna’s interim analysis of its Phase III norovirus study. Moderna recently shared that the trial didn’t hit the statistical criteria for early success and that it intends to add another cohort. Does management see this result as positive or as a barrier to Vaxart’s competitive and partnering position?

Steve Lo

executive
#22

Right. So, as I mentioned before, and as I was saying, what this question is really getting at is whether it's good or bad. I'd describe it once more as a mixed situation. When it comes to competition, it definitely works in our favor. But there's a risk to watch: if I were a possible partner, they'd be looking at us and wondering why Moderna is taking so long. And that would factor into their thinking when they discuss with us how a norovirus trial should be run. Sean may have a scientific or statistical take on this too, if you'd like to jump in.

Sean Tucker

executive
#23

Okay, once more, I would really enjoy making guesses, so let me share a bit about what is going through my mind. Naturally, we do not possess Moderna's statistical analysis plan, so the exact reason their interim analysis did not succeed is unknown to us. What we do know, though, is that the study is still going on. If that is the case, then what could be happening, and what strikes me as probable, is that some efficacy was observed, yet certain pre-specified endpoints were not reached. Still, in my view, carrying the study onward counts as a good development, since they recognized — they perceive worth in this indication, and there is justification for proceeding. As I have stated on many occasions, we hold the belief that anti-bodies in the intestine matter for shielding people against norovirus, and we are aware that our oral tablets will outperform an injected vaccine when it comes to listing these. Thus we feel quite optimistic that our vaccine might deliver superior efficacy compared with Moderna's vaccine.

David Carey

executive
#24

Thanks, Sean and Steve. Steve, I have one more thing to ask you. What's the reason the norovirus timeline is no longer included in the corporate slide deck? Also, why doesn't the quarterly business update make any reference to that program?

Steve Lo

executive
#25

Yes, regarding the second part of your question, the reason it might not have appeared in the quarterly business update is that we have plenty of positive data on COVID to share, so we wanted to emphasize that since it's the near-term focus, along with, naturally, the BARDA agreement. That explains why our emphasis has shifted more toward COVID. As for the norovirus timeline, another point we want to be fully transparent about is that we keep pitching this opportunity to prospective partners. It's a work in progress. And given that it's a work in progress, plus the fact that funding hasn't been secured — and we'll pursue non-dilutive funding too, not only funding from a potential partner — but beyond that, since we lack funding, I believe it's too early for us to specify when that Phase II study would begin, because it hinges on funding. So that's why the corporate deck has been updated now.

David Carey

executive
#26

All right, thanks, Steve. Turning now to a few questions about BARDA. James, can you handle this one, please? With the extra $29 million in funding from BARDA, what further analysis is being carried out? And what was the reason it wasn't factored in when the trial began, instead of being added before unblinding? Was it Vaxart that asked for that $29 million? Or was it BARDA that asked for additional analysis, and Vaxart replied it would take $29 million?

James Cummings

executive
#27

Appreciate you asking. The $29 million that came through the BARDA contract modification covers the last stretch of trial execution and also broadens the exploratory work on safety, immunogenicity, and efficacy — things like more in-depth genomic sequencing of subvariants and expanded profiling of mucosal and cellular biomarkers throughout the main cohort of more than 5,000 participants. Certain pieces of that analytical effort had initially been envisioned as a second phase once the first data came out, so we're quite happy BARDA chose to pay for this work and let it get underway even prior to the study reaching final completion. What this modification amounts to is, honestly, a two-way agreement. Under its Project NextGen mandate, BARDA needed high-resolution exploratory data to determine whether oral mucosal technology truly provides distinctive benefits. And Vaxart put together the operational budget and the $29 million figure needed to finish the trial and hand over those thorough data sets. Hopefully that addresses what you asked.

David Carey

executive
#28

Appreciate that, James. Sean, here's the next one for you. Leadership frequently mentions looking for funding that doesn't dilute, and you did a great job securing that through the Dynavax partnership. Investors frequently notice RFIs backed by the government along with grant submissions that look like a really good match for these Vaxart pipelines. Could you say whether Vaxart takes an active part in those RFIs, or whether more government money is viewed as improbable until the Phase IIb is finished?

Sean Tucker

executive
#29

Absolutely, and I appreciate you asking. Once more, when it comes to obtaining non-dilutive funding, Vaxart has a solid, well-established history of getting it done. The clearest example would be the significant award we received through BARDA's Project NextGen, though we've also completed work alongside the Gates Foundation. In earlier years, we held onto grants from the NIH as well. So on that front, our record speaks well for itself. I can promise you this: we are actively and aggressively looking at a range of ways to lengthen our cash runway, whether through business development or non-dilutive funding sources, and our aim is to hit the clinical and regulatory milestones ahead while driving shareholder value as high as possible. One thing to remember, however — for competitive reasons, we stay quiet about whatever dilutive efforts we might be chasing right now, but once funding is locked in, we'll share the details.

David Carey

executive
#30

Appreciate that, Sean. Jeroen, this next one's directed at you. With Vaxart's announced cash runway extending to the second quarter of 2027, the scheduled end of Phase II meeting with the FDA, and the terms along with the decision time line in the Sanofi contract, is management anticipating an opt-in decision from Sanofi prior to the point when the company's existing cash runway runs out? And if that's not the case, what's management's plan for funding operations up to the opt-in decision point while keeping shareholder dilution as low as possible?

Jeroen Grasman

executive
#31

Absolutely. Thanks, David. So yes, as a team, we're in complete alignment on the necessity of lengthening our runway — that includes the Sanofi opt-in mentioned in the question, and also supporting advancement of the encouraging pipeline programs we've discussed, which are norovirus, flu, and HPV. From my seat as CFO, the clear first priority is financial discipline. That means cost efficiency and making sure every dollar of spending supports corporate priorities and helps us reach meaningful milestones. Like Steve said, and Sean just mentioned, we're looking at every avenue for securing additional funding — I mean from non-dilutive sources, such as the government, NGOs including the Gates Foundation, and pursuing strategic industry partners for our programs. The last thing I'd point out is that we continue to have availability under that $25 million share purchase agreement we put in place during the recent quarter with Lincoln Park Capital. That's $25 million we can tap flexibly, whenever we choose, on terms I'd describe as generally quite favorable relative to a bigger, more dilutive raise. So I'll hand it back to you, David.

David Carey

executive
#32

Appreciate that, Jeroen. The following question comes from Sean. At this point, I'd like to ask whether Dr. Sean Tucker, working alongside the scientific team, has gone through the pre-clinical or clinical sample data sets that already exist in order to determine if the mucosal CD8 T cells generated by Vaxart naturally carry CD39. Should Vaxart proceed to the next clinical phase for HPV, which path is intended — option A, moving the present formulation into trials while incorporating CD39 expression as an exploratory biomarker or endpoint, or option B, finishing pre-clinical optimization so that robust CD39 solicitation is guaranteed before the clinical protocol is finalized.

Sean Tucker

executive
#33

Absolutely. I appreciate the question, and I appreciate you highlighting how important CD39 is — I find it to be a genuinely compelling biomarker. We didn't examine it during the early pre-clinical work, though tracking it in upcoming studies is certainly something that interests us.

David Carey

executive
#34

Thanks, Sean. The following question is directed at you as well. Moderna just received FDA approval for mRESVIA — how does Vaxart view that decision? And what bearing does it have on the flu vaccine program you're running?

Sean Tucker

executive
#35

Absolutely. It's a thrilling moment. To start, we want to note that this marks a major leap for the vaccine sector—more choices when it comes to public health matter greatly to us. Moderna has clearly demonstrated that the marketplace is primed for innovative solutions, not merely traditional flu shots. Certain vaccine programs might boost effectiveness, ease of use, or achieve both; and once more, from where we sit, as we move our oral flu vaccine candidate ahead through clinical trials, we believe our position is unlike any other to provide what we see as the final destination for respiratory immunization: no needles, stable at room temperature, mucosal defense, all within an easy-to-take pill.

David Carey

executive
#36

Appreciate that, Sean. Steve, this next one's directed at you. Now that Dr. Breitmeyer has come onto the Board and brings such a remarkable oncology background, ought we to anticipate that Vaxart's HBV program will speed up over the next several months?

Steve Lo

executive
#37

We are truly grateful to have Dr. Breitmeyer on our Board. With his deep background in vaccines and oncology—just to mention a couple of other therapeutic areas—he is an excellent fit for us. And as I mentioned before, as part of our strategy with the Board, we've established a clinical and regulatory affairs committee; so examining our full portfolio, with suggestions on where to speed things up and what's high value, will fall under that committee's responsibilities; and there are numerous inputs feeding into that. And of course, with Dr. Breitmeyer serving on the Board, we'll be carrying that out; and additionally, forming this Clinical and Regulatory Affairs Committee was also included in the settlement, under the cooperation agreement with the stockholder group. I'd also like to pause briefly to recognize and thank the stockholder group. We've had conversations and have been engaging together as a group, and they've been supportive when it comes to discussing next steps for how we involve stockholders; so once more, thank you for collaborating with us on that settlement.

David Carey

executive
#38

Steve, here's one more thing I'd like to ask you. If Vaxart isn't able to secure a fitting partnership, could the company talk about the expected schedule for moving the norovirus program forward, and give us a bit more detail about what its plan looks like.

Steve Lo

executive
#39

Right, so the key thing here—and this ties back to what Jeroen mentioned regarding our cash runway—is that having a partner capable of financing this project through to its next stage really matters to us. That's the reason we're investing considerable effort in pitching this asset as a partnership opportunity. Should we hit some obstacles on that front, I'd note that at the same time, we've been in conversations with alternative funding avenues—non-dilutive ones, including foreign governments outside America, to offer just one illustration. So the strategy is to keep pushing this forward. I should add that updates on this may come less frequently. And should we ever choose to stop pursuing it, naturally we'd disclose that publicly too. That said, many questions tend to arise during these partnership talks, among them market size—there can be differing perspectives between us on that. Quite a few of these prospective partners were additionally awaiting the outcome with Moderna, so my sense is that's still being factored into their evaluation. But that simply offers a sense of where things stand concerning the norovirus asset.

David Carey

executive
#40

Steve, I have one more thing to ask you. Since you run a publicly traded business, what message do you have for those shareholders who have stayed with you over the long haul — the ones who put money in when things were rough and made sure the lights stayed on?

Steve Lo

executive
#41

Okay, so the main thing is, we absolutely intend to keep things running, since — Sean's right beside me here, and he's nodding — we genuinely have faith in the science; we're determined to push this as far as possible, and the fantastic ideas Sean brought as this company's founder, we're dedicated to carrying those forward. So here's what I'd say to investors: stay with us. I mean, we truly have confidence in what we're doing. We won't quit. Frequently, difficult decisions are necessary; and among those difficult decisions is what we regrettably had to do in the prior year, when we needed to cut expenses, and we needed to let a small number of workers go. And simultaneously, we also must keep the people currently working here inspired. But looking at it from an investor's perspective, I'll say I completely agree with everyone that we think this asset — these assets are priced below their worth. We'd like the share price to climb; we'll continue battling, and we'll put in as much effort as possible to make sure of that. Our vision rests on the fact that when we speak with lots of investors at times, we point out that if they could choose between getting a shot for a vaccine or taking a pill, I mean, the investors themselves would surely pick the same option. So we'll keep on doing what we've been doing. I truly wish to recognize and thank the investors for remaining with us, for being involved, for posing excellent questions, and I really appreciate your ongoing engagement.

David Carey

executive
#42

Appreciate that, Steve. And in fact, Steve, I'll hand things back over to you in case you have any final comments.

Steve Lo

executive
#43

Alright, so first off, I want to express my appreciation to all of you for being here today, for sending in your questions, and even for the challenging ones. During this quarter, Vaxart achieved meaningful advancement, with positive head-to-head safety results coming from the sentinel cohort of our Phase II COVID-19 trial, along with government support for broader analytics and a defined route ahead toward complete study data—so we feel our position is strong when it comes to showing what our oral pill vaccine platform is genuinely worth. Each step forward we take stems from our dedication to patients, people enrolled in trials, and public health across the globe. With National Immunization Awareness Month happening this August, it serves as a reminder that conventional vaccines continue to create far too many obstacles. That change has now been propelled by Vaxart. We stay committed to providing convenient, needle-free, oral pill vaccines that simplify immunization, expand access worldwide, and safeguard communities everywhere, all while creating lasting long-term value for our stockholders. In closing, I'd like to thank our stockholders for participating in productive conversations with us, and also our skilled Vaxart team for their ongoing effort and enthusiasm. I appreciate everyone's time, and I hope you have a wonderful evening.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Vaxart, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Vaxart, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Vaxart, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.